RNAC · NASDAQ
Cartesian Therapeutics (RNAC) Stock Price & Fundamentals
Cartesian Therapeutics (RNAC) closed at $767.12 on Oct 9, 2026, down 0.53% from the previous close of $771.19.
Share price, past year
1Y +8.08%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $767.12 |
| Sep 30, 2026 | $762.05 |
| Aug 31, 2026 | $762.20 |
| Jul 31, 2026 | $701.70 |
| Jun 30, 2026 | $730.93 |
| May 29, 2026 | $687.25 |
| Apr 30, 2026 | $723.03 |
| Mar 31, 2026 | $709.77 |
| Feb 27, 2026 | $679.36 |
| Jan 30, 2026 | $729.57 |
| Dec 31, 2025 | $681.92 |
| Nov 28, 2025 | $691.43 |
| Oct 31, 2025 | $738.24 |
Key statistics
- Market cap
- $23.04B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $0.00
- Net income (TTM)
- −$151.89M
- Shares outstanding
- 30M
- Dividend yield
- —
- 52-week range
- $662.67 – $782.40
Cartesian Therapeutics's market cap is $23.04B, based on a share price of $767.12 and 30M shares outstanding as of Jun 30, 2026.
Financials
Cartesian Therapeutics reported revenue of $400.00K for fiscal 2025, down 98.95% from fiscal 2024.
Cartesian Therapeutics reported a net loss of $130.30M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $400.00K | −99.0% | −$130.30M | −32,575.5% | −$5.02 | −$79.40M |
| FY2024ended Dec 31, 2024 | $38.28M | +47.2% | −$77.42M | −202.3% | −$4.49 | −$32.77M |
| FY2023ended Dec 31, 2023 | $26.00M | −76.5% | −$219.71M | −844.9% | −$49.76 | −$51.37M |
| FY2022ended Dec 31, 2022 | $110.78M | +30.2% | $35.38M | 31.9% | $3.00 | −$32.83M |
| FY2021ended Dec 31, 2021 | $85.08M | +412.6% | −$25.69M | −30.2% | −$6.61 | −$61.47M |
| FY2020ended Dec 31, 2020 | $16.60M | +148.6% | −$68.88M | −415.0% | −$20.42 | $34.07M |
| FY2019ended Dec 31, 2019 | $6.68M | +639.4% | −$55.35M | −829.0% | −$36.64 | −$51.48M |
| FY2018ended Dec 31, 2018 | $903.00K | +336.2% | −$65.34M | −7,235.4% | — | −$60.05M |
| FY2017ended Dec 31, 2017 | $207.00K | −97.4% | −$65.32M | −31,556.0% | — | −$52.76M |
| FY2016ended Dec 31, 2016 | $8.08M | — | −$36.21M | −448.0% | — | −$20.34M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | $15.77M | $0.46 |
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$39.18M | −$1.46 |
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$92.58M | — |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$35.90M | −$1.38 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | $15.89M | $0.50 |
| Q1 FY2025ended Mar 31, 2025 | $400.00K | −$17.71M | −$0.68 |
| Q4 FY2024ended Dec 31, 2024 | −$836.00K | −$10.25M | — |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$24.18M | −$1.13 |
Company profile
- Name
- Cartesian Therapeutics, Inc.
- Ticker
- RNAC
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 7495 New Horizon Way, Frederick, MD 21703
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001453687
Recent SEC filings
- Sep 29, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jun 17, 2026
- Jun 9, 2026
- May 26, 2026
- Apr 30, 2026
- Apr 30, 2026
Frequently asked questions
What is Cartesian Therapeutics's stock price?
Cartesian Therapeutics (RNAC) closed at $767.12 on Oct 9, 2026, down 0.53% from the previous close of $771.19.
What is Cartesian Therapeutics's market cap?
Cartesian Therapeutics's market cap is $23.04B, based on a share price of $767.12 and 30M shares outstanding as of Jun 30, 2026.
How much revenue does Cartesian Therapeutics make?
Cartesian Therapeutics reported revenue of $400.00K for fiscal 2025, down 98.95% from fiscal 2024.
Does Cartesian Therapeutics pay a dividend?
Cartesian Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Cartesian Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures